Meta analysis on the efficacy of pharmacotherapy versus placebo on anorexia nervosa

Journal of Eating Disorders

Jack Dekker²  Pim Cuijpers³  Elske van de Berg²  Georgia Katsaragaki²  Laura Houtzager¹  Jasmijn de Vos² 

[1] De Viersprong Mental Health Institute, Bergen op Zoom, the Netherlands;Arkin Mental Health Institute, Klaprozenweg 111, Amsterdam, 1070, AV, the Netherlands;Vrije Universiteit, Amsterdam, the Netherlands

关键词: Meta-analysis;    Anorexia nervosa;    Treatment;    Placebo;    Pharmacotherapy;   

Others  :  1133354
DOI  :  10.1186/s40337-014-0027-x

 received in 2013-11-15, accepted in 2014-09-02,  发布年份 2014

【 摘 要 】

Background

Anorexia Nervosa (AN) has a devastating impact on the psychological and physical well being of affected individuals. There is an extensive body of literature on interventions in AN, however more studies are needed to establish which form of pharmacotherapy is effective. The few meta-analyses that have been done are based on one type of medication only. This article is the first to present data on three different, most commonly used, forms of pharmacotherapy. The primary objective of this meta-analysis was to create an overview and to determine the efficacy of three forms of pharmacotherapy (antidepressants, antipsychotics, hormonal therapy) compared to treatment with placebo in patients with AN.

Method

A systematic literature search was performed to identify all randomized controlled intervention trials investigating the effectiveness of pharmacotherapy for AN within the following databases: PubMed, PsycINFO, Embase and Cochrane Library. In addition, 32 relevant reviews and meta-analyses were screened for additional intervention studies. A meta-analysis was performed on a total of 18 included studies (N = 869). Efficacy was measured in terms of weight gain or weight restoration.

Results

The pooled effect sizes indicating the difference between antidepressants and placebo, and between antipsychotics and placebo on weight were not significant. Because of the small sample size no meta regression and subgroup analyses could be conducted. The pooled effect size indicating the difference between hormonal therapy and the placebo condition on weight (all weight measures) at post-treatment was 0.42 (95% CI: 0.11 ~ 0.73), which was significant. For hormonal therapy heterogeneity was high (I² = 64.70). No evidence for publication bias was found. Meta-regression analyses of the weeks of medication treatment (slope = −0.008) yielded a significant effect (p = 0.04).

Conclusions

In this study we found that hormonal therapy has a significantly larger effect on weight compared to placebo in the treatment of AN. However for these analyses heterogeneity was high, which means that these results have to be regarded with caution. We found that anti-depressants and antipsychotics had no significant effect on weight compared to placebo in the treatment of AN, although the power to detect significant effects was too low.

【 授权许可】

   
2014 de Vos et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders: Compendium 2006. American Psychiatric Pub, Arlington, VA, USA; 2006.
• [2]Hudson JI, Hiripi E, Pope HG Jr, Kessler RC: The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry 2007, 61:348-358.
• [3]Attia E, Schroeder L: Pharmacologic treatment of anorexia nervosa: where do we go from here? Int J Eat Disord 2005, 37(Suppl):S60-S63.
• [4]Claudino AM, Silvade Lima M, Hay PPJ, Bacalthcuk J, Schmidt UUS, Treasure J: Antipsychotic Drugs for Anorexia Nervosa (Protocol). The Cochrane Library, England; 2009.
• [5]Mondraty N, Birmingham CL, Touyz S, Sundakov V, Chapman L, Beumont P: Randomized controlled trial of olanzapine in the treatment of cognitions in anorexia nervosa. Australas Psychiatry 2005, 13:72-75.
• [6]Bosanac P, Norman T, Burrows G, Beumont P: Serotonergic and dopaminergic systems in anorexia nervosa: a role for atypical antipsychotics? Aust N Z J Psychiatry 2005, 39:146-153.
• [7]Mitchell JE, Steffen K, Cook MT, Roerig J: Pharmacologic and psychotherapeutic treatment of anorexia nervosa. Womens Health (Lond Engl) 2005, 1:115-123.
• [8]Agras WS, Robinson AH: Forty years of progress in the treatment of the eating disorders. Nord J Psychiatry 2008, 62(Suppl 47):19-24.
• [9]Kishi T, Kafantaris V, Sunday S, Sheridan EM, Correll CU: Are antipsychotics effective for the treatment of anorexia nervosa? Results from a systematic review and meta-analysis. J Clin Psychiatry 2012, 73:e757-e766.
• [10]Lebow J, Sim LA, Erwin PJ, Murad MH: The effect of atypical antipsychotic medications in individuals with anorexia nervosa: a systematic review and meta-analysis. Int J Eat Disord 2012, 46:332-339.
• [11]Sim LA, McGovern L, Elamin MB, Swiglo BA, Erwin PJ, Montori VM: Effect on bone health of estrogen preparations in premenopausal women with anorexia nervosa: a systematic review and meta-analyses. Int J Eat Disord 2010, 43:218-225.
• [12]Powers PS, Santana C: Available pharmacological treatments for anorexia nervosa. Expert Opin Pharmacother 2004, 5:2287-2292.
• [13]Lipsey MW, Wilson DB: The efficacy of psychological, educational, and behavioral treatment. Confirmation from meta-analysis. Am Psychol 1993, 48:1181-1209.
• [14]Duval S, Tweedie R: Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000, 56:455-463.
• [15]Higgins JTP, Green SE: Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, England; 2009.
• [16]Borenstein M, Hedges LVHJPT, Rothstein HR: Introduction to Meta-Analysis. Wiley, Chichester; 2009.
• [17]Attia E, Haiman C, Walsh BT, Flater SR: Does fluoxetine augment the inpatient treatment of anorexia nervosa? Am J Psychiatry 1998, 155:548-551.
• [18]Attia E, Kaplan AS, Walsh BT, Gershkovich M, Yilmaz Z, Musante D, Wang Y: Olanzapine versus placebo for out-patients with anorexia nervosa. Psychol Med 2011, 41:2177-2182.
• [19]Bissada H, Tasca GA, Barber AM, Bradwejn J: Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2008, 165:1281-1288.
• [20]Brambilla F, Monteleone P, Maj M: Olanzapine-induced weight gain in anorexia nervosa: involvement of leptin and ghrelin secretion? Psychoneuroendocrinology 2007, 32:402-406.
• [21]Brambilla F, Garcia CS, Fassino S, Daga GA, Favaro A, Santonastaso P, Ramaciotti C, Bondi E, Mellado C, Borriello R, Monteleone P: Olanzapine therapy in anorexia nervosa: psychobiological effects. Int Clin Psychopharmacol 2007, 22:197-204.
• [22]Divasta AD, Feldman HA, Giancaterino C, Rosen CJ, Leboff MS, Gordon CM: The effect of gonadal and adrenal steroid therapy on skeletal health in adolescents and young women with anorexia nervosa. Metabolism 2012, 61:1010-1020.
• [23]Fazeli PK, Lawson EA, Prabhakaran R, Miller KK, Donoho DA, Clemmons DR, Herzog DB, Misra M, Klibanski A: Effects of recombinant human growth hormone in anorexia nervosa: a randomized, placebo-controlled study. J Clin Endocrinol Metab 2010, 95:4889-4897.
• [24]Grinspoon S, Baum H, Lee K, Anderson E, Herzog D, Klibanski A: Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa. J Clin Endocrinol Metab 1996, 81:3864-3870.
• [25]Grinspoon S, Thomas L, Miller K, Herzog D, Klibanski A: Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa. J Clin Endocrinol Metab 2002, 87:2883-2891.
• [26]Halmi KA, Eckert E, LaDu TJ, Cohen J: Anorexia nervosa. Treatment efficacy of cyproheptadine and amitriptyline. Arch Gen Psychiatry 1986, 43:177-181.
• [27]Hill K, Bucuvalas J, McClain C, Kryscio R, Martini RT, Alfaro MP, Maloney M: Pilot study of growth hormone administration during the refeeding of malnourished anorexia nervosa patients. J Child Adolesc Psychopharmacol 2000, 10:3-8.
• [28]Kafantaris V, Leigh E, Hertz S, Berest A, Schebendach J, Sterling WM, Saito E, Sunday S, Higdon C, Gollden NH, Malhotra AK: A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa. J Child Adolesc Psychopharmacol 2011, 21:207-212.
• [29]Lacey JH, Crisp AH: Hunger, food intake and weight: the impact of clomipramine on a refeeding anorexia nervosa population. Postgrad Med J 1980, 56(Suppl 1):79-85.
• [30]Miller KK, Meenaghan E, Lawson EA, Misra M, Gleysteen S, Schoenfeld D, Herzog D, Klibanski A: Effects of risedronate and low-dose transdermal testosterone on bone mineral density in women with anorexia nervosa: a randomized, placebo-controlled study. J Clin Endocrinol Metab 2011, 96:2081-2088.
• [31]Misra M, Katzman D, Miller KK, Mendes N, Snelgrove D, Russell M, Goldstein MA, Ebrahimi S, Clauss L, Weigel T, Mickley D, Schoenfeld DA, Herzog DB, Klibanski A: Physiologic estrogen replacement increases bone density in adolescent girls with anorexia nervosa. J Bone Miner Res 2011, 26:2430-2438.
• [32]Strokosch GR, Friedman AJ, Wu SC, Kamin M: Effects of an oral contraceptive (norgestimate/ethinyl estradiol) on bone mineral density in adolescent females with anorexia nervosa: a double-blind, placebo-controlled study. J Adolesc Health 2006, 39:819-827.
• [33]Vandereycken W: Neuroleptics in the short-term treatment of anorexia nervosa. A double-blind placebo-controlled study with sulpiride. Br J Psychiatry 1984, 144:288-292.
• [34]Walsh BT, Kaplan AS, Attia E, Olmsted M, Parides M, Carter JC, Pike KM, Devlin MJ, Woodside B, Roberto CA, Rockert W: Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial. JAMA 2006, 295:2605-2612.
• [35]Walsh BT, Devlin MJ: Eating disorders: progress and problems. Science 1998, 280:1387-1390.
• [36]Brody H: The placebo response. J Fam Pract 2000, 49:649-654.